 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > Maxim Pharmaceuticals, Inc.
 |
Maxim Pharmaceuticals, Inc. |
 |
 |
 |
PROFILE |
 |
Development-stage Maxim Pharmaceuticals is maximizing its product line. The company's Ceplene (formerly Maxamine) is in trials for the treatment of skin cancer and leukemia. With partner Hoffman-La Roche, the firm is developing a potential treatment for renal cancer and hepatitis C using Ceplene and La Roche's interferon-alpha agent in combination. Maxim believes Ceplene protects immune system cells and stimulates them to destroy cancerous cells. It is designed to be administered on an outpatient basis. Maxim Pharmaceuticals is also developing MaxDerm, a topical treatment for cold sores, canker sores, shingles, and burns, as well as oral mucositis, a side effect of chemotherapy.
COMPETITION |
 |
AVANIR Pharmaceuticals (AVN)
Immunex Corporation (IMNX)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: September
2000 Sales (mil.): 1.40
1-Yr. Sales Growth: 27.3%
Employees: 144
Revenue per employee: $9,722.22
KEY PEOPLE |
 |
Larry G. Stambaugh
CEO
Dale A. Sander
CFO
CONTACT INFO |
 |
8899 University Center Ln., Ste. 400
San Diego, CA 92122
US
Phone: 858-453-4040
Fax: 858-453-5005
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |